Navigation Links
Xeomin® (incobotulinumtoxinA) Data To Be Presented At The 71st Annual Assembly Of The American Academy Of Physical Medicine And Rehabilitation
Date:11/5/2010

inum toxin. Patients with neuromuscular disorders may be at increased risk of clinically significant effects including severe dysphagia and respiratory compromise from typical doses of XEOMIN.

ADVERSE REACTIONSCervical Dystonia:  The most commonly observed adverse reactions (incidence ≥10% of patients and twice the rate of placebo) for XEOMIN 120 Units and XEOMIN 240 Units, respectively, were: dysphagia (13%, 18%), neck pain (7%, 15%), muscle weakness (7%, 11%), and musculoskeletal pain (7%, 4%).

Blepharospasm: The most common adverse reactions (incidence ≥10% of patients and twice the rate of placebo) for XEOMIN were eyelid ptosis (19%), dry mouth (16%), visual impairment (12%), diarrhea (8%), and headache (7%).

DRUG INTERACTIONSConcomitant treatment of XEOMIN and aminoglycoside antibiotics, spectinomycin, or other agents that interfere with neuromuscular transmission (e.g., tubocurarine-like agents), or muscle relaxants, should be observed closely because the effect of XEOMIN may be potentiated.

USE IN PREGNANCYPregnancy Category C: There are no adequate and well-controlled studies in pregnant women. XEOMIN should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Please see full prescribing information for XEOMIN, including Boxed WARNING, available at www.XEOMIN.com. About MerzMerz Pharmaceuticals, LLC is a part of the Merz Group of companies and was established in 1995 to develop and commercialize products for the Merz Group. Areas of therapeutic focus include Neurology, Dermatology, and Podiatry.

With a 102 year heritage, the Merz Group is known worldwide for its development of original compounds and formulations for medical professionals and consumers in 90 countries. Globally, Merz is a leader in the development of pharmaceuticals for the treatment of neurological and psycholo
'/>"/>

SOURCE Merz Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Xeomin® (incobotulinumtoxinA) - a Botulinum Toxin Free From Accessory Proteins - Now Available in the U.S.
2. FDA Approves Merz Pharmaceuticals Xeomin® (incobotulinumtoxinA) for the Treatment of Cervical Dystonia and Blepharospasm
3. Romark Announces Data Presented at AASLD Meeting 2010
4. Medivir Notes That Partner Tibotec Announced Week 24 Interim Results From Phase 2b TMC435 PILLAR Study to be Presented as a Late-Breaker at AASLD
5. ANA598 Data Presented at AASLD Highlight Positive Clinical Profile of DAA Entering Phase IIb
6. Over 20 New Clinical Studies Presented on Masimo Noninvasive Patient Monitoring Technologies at the American Society of Anesthesiologists Annual Meeting
7. New Analysis of CAMBIA™ Pivotal Data to be Presented at the 4th World Congress on Controversies in Neurology
8. Positive Results From LigoCytes Norovirus Vaccine Challenge Study Presented at IDSA Annual Meeting
9. Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
10. Celsion Announces ThermoDoxs Prominence in Abstracts Presented at the 2nd International MR-Guided Ultrasound Symposium
11. New FORTEO® and EVISTA® Data to be Presented at Premiere Scientific Meeting for Bone and Mineral Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... , Nov. 21, 2014 ... the European Medicines Agency (EMA) has granted ... company,s lead product candidate, for the treatment ... a rare, severely disabling genetic disease characterized ... swelling (flare-ups) and new abnormal bone formation. ...
(Date:11/21/2014)... 20, 2014  RedRick Technologies, a provider of ... room environment guidance, has helped the new Penn ... room, which may also serve as a model ... "In line with the tenets ... Radiology,s Imaging 3.0 ™ initiative, the new ...
(Date:11/21/2014)... CORAL GABLES, Fla. , Nov. 20, 2014 /PRNewswire/ ... working to become the first U.S. commercial producer of ... signed a contract with INVAP to design ... Alachua, Fla. Mo-99 is the parent isotope ... nuclear medicine procedures worldwide. In 2012, Congress passed legislation ...
Breaking Medicine Technology:Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 2Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 3RedRick Technologies Helps Penn Radiology Implement New Radiology Reading Room Concepts 2RedRick Technologies Helps Penn Radiology Implement New Radiology Reading Room Concepts 3Coqui RadioPharmaceuticals Inks Deal With INVAP 2
... Trust, Inc. (NYSE: BMR ) announced ... with Omeros Corporation (NASDAQ: OMER ) ... Seattle, Washington.  A clinical-stage biopharmaceutical company committed to ... coagulopathies and disorders of the central nervous system, Omeros ...
... Feb. 1, 2012 Novartis announced today that following ... (FDA) has approved an update to the Gleevec ® ... of treatment after surgery for adult patients with KIT ... of recurrence inclusion criteria of the pivotal trial. This ...
Cached Medicine Technology:BioMed Realty and Omeros Sign New 64,500 Square Foot Lease in Seattle 2BioMed Realty and Omeros Sign New 64,500 Square Foot Lease in Seattle 3BioMed Realty and Omeros Sign New 64,500 Square Foot Lease in Seattle 4FDA approves Novartis drug Gleevec® label recommending extending treatment to three years for certain GIST patients after surgery 2FDA approves Novartis drug Gleevec® label recommending extending treatment to three years for certain GIST patients after surgery 3FDA approves Novartis drug Gleevec® label recommending extending treatment to three years for certain GIST patients after surgery 4FDA approves Novartis drug Gleevec® label recommending extending treatment to three years for certain GIST patients after surgery 5FDA approves Novartis drug Gleevec® label recommending extending treatment to three years for certain GIST patients after surgery 6FDA approves Novartis drug Gleevec® label recommending extending treatment to three years for certain GIST patients after surgery 7FDA approves Novartis drug Gleevec® label recommending extending treatment to three years for certain GIST patients after surgery 8
(Date:11/23/2014)... November 23, 2014 The FDA is ... Common, **FDAnews On-Demand Webinar**, Dec. 11, 2014 ? Any ... The FDA’s focus on promotional activities is no longer ... Now they're looking at websites, Twitter, journal articles, TV ... for Thursday, Dec. 11, for On-Demand access to Timothy ...
(Date:11/23/2014)... 23, 2014 BambooFlooringChina.com , the world’s ... click strand woven bamboo flooring collection. Now, the business ... the company’s CEO, the promotion is valid until Dec. 20, ... with a smooth and dust-free surface, which makes it very ... the industry, the company wants to make its website the ...
(Date:11/22/2014)... A new AlignLife Chiropractic & Natural ... downtown Greenville area. Dr. Chelsea Sineath, owner and chiropractor ... open her own clinic after working in another AlignLife ... , AlignLife believes that the body can heal ... on chiropractic care and rehabilitation to allow the spine ...
(Date:11/22/2014)... November 23, 2014 Recently, UWDress.com, a successful ... formal wedding guest attire in order to prepare for ... prices, up to 70% off. , UWDress.com is a ... are very beautiful, especially the new items -- formal wedding ... in the current market, including superstar and princess. As one ...
(Date:11/22/2014)... BambooFlooringChina.com is a famous brand in the ... new collection of bamboo mats ; the new models ... , According to the sales manager of BambooFlooringChina.com, ... a highly renewable resource. Their bamboo mats are 100% made ... comes from natural bamboo with caramel bamboo strips. ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 2Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 3Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 4Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 5Health News:Click Strand Woven Bamboo Flooring From Famous Bamboo Flooring Company BambooFlooringChina.com 2Health News:AlignLife of Downtown Greenville is Now Open and Accepting New Patients 2Health News:Formal Wedding Guest Attire Added to UWDress.com 2Health News:Trendy Bamboo Mats Online Now By BambooFlooringChina.com 2
... ... company, now offers their clients a choice between a Flat Fee Plan and a Monthly ... Miami, FL ... cash strapped plaintiffs don’t have to wait for their lawsuits to recover, they can get ...
... NASHVILLE, Tenn., Dec. 10 Pathological gambling can be ... inhibitions, according to researchers at the annual meeting of ... outcomes in gamblers treated with medications often used for ... his team at the University of Minnesota used tasks ...
... The 2009 American College of Neuropsychopharmacology Annual Meeting ... schizophrenia and treatment for gambling addiction. Study highlights ... Techniques to Assess PTSD. Working with Iraq and ... may be useful to evaluate PTSD and develop ...
... ... a leading neurologist, Dr. Alexander Mauskop, renowned headache expert and founder of the New ... ... 9, 2009 -- A powerful headache medicine developed by a leading neurologist for his ...
... , WARRINGTON, Pa., Dec. 9 Last year Special Equestrians was ... part of $25,000 in PR service grants. "We,ve always taken corporate ... a warm and fuzzy feeling to do what little we can ... co-founder, Christopher L. Simmons. "We learned many years ago that it ...
... Award Will Create New Construction and Permanent Jobs in the South ... Additional 12,000 Residents , NEW YORK, Dec. 9 ... Reinvestment Act (Recovery Act) grant to support a new addition to ... announced by President Barack Obama as part of his plan to ...
Cached Medicine News:Health News:Injury Funds Now To the Rescue with New Lawsuit Funding Service 2Health News:Pathological Gambling May Be Successfully Treated With Medications for Substance Addiction 2Health News:Late-breaking brain and behavior research presented at ACNP annual meeting this week 2Health News:Breakthrough Approach to Age-old Ailment, Renowned Doctor Introduces Powerful Headache Medicine 2Health News:Breakthrough Approach to Age-old Ailment, Renowned Doctor Introduces Powerful Headache Medicine 3Health News:Nonprofit Partners With PR Company and Gains International Attention 2Health News:$12 Million American Recovery and Reinvestment Act Grant Awarded to Urban Health Plan, Inc. (UHP) 2Health News:$12 Million American Recovery and Reinvestment Act Grant Awarded to Urban Health Plan, Inc. (UHP) 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: